Marino Scherillo

Benevento, 82100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

Journal: International journal of molecular sciences

Published: May 04, 2026

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

Journal: International journal of molecular sciences

Published: March 12, 2026

Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.

Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.

Journal: Healthcare (Basel, Switzerland)

Published: September 15, 2025

Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients.

Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients.

Journal: Journal of cardiovascular pharmacology

Published: July 14, 2025

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.

Journal: International journal of molecular sciences

Published: June 12, 2025

In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.

In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.

Journal: Cancers

Published: February 21, 2025

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

Journal: International journal of molecular sciences

Published: September 06, 2024

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.

Journal: Cancers

Published: February 13, 2024

ANMCO Position paper - 2023 ANMCO States General: The shortage of healthcare personnel in the cardiology field

ANMCO Position paper - 2023 ANMCO States General: The shortage of healthcare personnel in the cardiology field

Journal: Giornale italiano di cardiologia (2006)

Published: January 25, 2024

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

Journal: Frontiers in cardiovascular medicine

Published: September 06, 2023

Identification and treatment of high-risk coronary atheromatous plaques: towards a shared strategy between the clinical and interventional cardiologist

Identification and treatment of high-risk coronary atheromatous plaques: towards a shared strategy between the clinical and interventional cardiologist

Journal: Giornale italiano di cardiologia (2006)

Published: July 01, 2023

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.

Journal: Frontiers in cardiovascular medicine

Published: May 31, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026